Access Bio (XKRX:950130) Change In Receivables : ₩3,375 Mil (TTM As of Mar. 2025)

View and export this data going back to 2013. Start your Free Trial

What is Access Bio Change In Receivables?

Access Bio's change in receivables for the quarter that ended in Mar. 2025 was ₩1,256 Mil. It means Access Bio's Accounts Receivable declined by ₩1,256 Mil from Dec. 2024 to Mar. 2025 .

Access Bio's change in receivables for the fiscal year that ended in Dec. 2024 was ₩11,665 Mil. It means Access Bio's Accounts Receivable declined by ₩11,665 Mil from Dec. 2023 to Dec. 2024 .

Access Bio's Accounts Receivable for the quarter that ended in Mar. 2025 was ₩6,311 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Access Bio's Days Sales Outstanding for the three months ended in Mar. 2025 was 26.53.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Access Bio's liquidation value for the three months ended in Mar. 2025 was ₩381,117 Mil.

Access Bio Change In Receivables Historical Data

The historical data trend for Access Bio's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Access Bio Change In Receivables Chart

Access Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-25,122.80

-102,205.08

-31,539.69

139,125.99

11,664.79

Access Bio Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															9,546.26	672.78	1,844.08	-398.33	1,256.29

Access Bio Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩3,375 Mil.

Access Bio (XKRX:950130) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Access Bio's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	6310.697	/	21706.506	*	91
=	26.53

2. In Ben Graham's calculation of liquidation value, Access Bio's accounts receivable are only considered to be worth 75% of book value:

Access Bio's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	440911.55	-	73953.803	+	0.75 * 6310.697	+	0.5 * 18851.838
=	381,117

Access Bio Change In Receivables Related Terms

Thank you for viewing the detailed overview of Access Bio's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Access Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Access Bio Inc (XKRX:950130) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Clyde Road, Suite A, Somerset, NJ, USA, 08873

Website

https://www.accessbio.net

Access Bio Inc is a United States based bio company engaged in the research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. The products are for the prevention and early diagnosis of infectious diseases. The company's core in vitro-diagnostic technology includes immunochemical, biochemical and molecular products. The company offers products for Rapid Diagnostic Tests including CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM; Biosensors product includes CareStart G6PD Biosensor, and Molecular Diagnostics products include CareStart HPV and CareStart CAH.

Access Bio Headlines

No Headlines